SRPT vs TRDA
SRPT: A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare genetic disorders. TRDA: Entrada is a clinical-stage biotech advancing exon-skipping genetic medicines with proprietary endosomal escape technology to treat neuromuscular diseases like DMD, with multiple programs in Phase 1/2 trials and an partnership with Vertex on a DM1 therapy.
Side-by-side fundamentals
| Metric | SRPT | TRDA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.82 | $6.15 | |
| Market cap as of 2026-07-23 | $1.7B | $239M | |
| P/E as of 2026-07-23 | 26.31 | n/a | |
| PEG as of 2026-07-23 | -23.53 | n/a | |
| Net margin as of 2026-07-23 | +3.0% | -2895.1% | SRPT higher |
| Gross margin as of 2026-07-23 | +70.5% | n/a | |
| Operating margin as of 2026-07-23 | -1.1% | -3109.3% | SRPT higher |
| ROE as of 2026-07-23 | +4.9% | -51.2% | SRPT higher |
| ROA as of 2026-07-23 | +1.9% | -42.2% | SRPT higher |
| Debt / equity as of 2026-07-23 | 0.56 | 0.00 | TRDA lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.2% | -96.7% | SRPT higher |
| Revenue CAGR (3y) SEC XBRL | +33.1% | -55.6% | SRPT higher |
| Beta as of 2026-07-23 | 0.19 | -0.28 | |
| 1-year return as of 2026-07-22 close | +16.2% | +5.2% | SRPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.